Hair Loss Research

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
MERCK
PROPECIA® (finasteride) 1mg This site is intended only for healthcare professionals of the United States,
its territories, and Puerto Rico. Non-US residents click here
PROPECIA Packaging
Home Prescribing Information Patient Product Information Patient Website
Product Data and Highlights
Prescribing PROPECIA
PROPECIA Overview
Prescribing Information
Patient Product Information
Timeline for Results
When to Start Treatment
Resources
5-Year Data
See the results of the longest reported controlled clinical study of male pattern hair loss.
View study results.
 
  • 9636003
  • PROPECIA® (Finasteride)

Results of clinical studies:

For 12 months, doctors studied over 1800 men aged 18 to 41 with mild to moderate amounts of ongoing hair loss. Of these men, approximately 1200 with hair loss at the top of the head participated in additional extension studies, resulting in a total study time of up to five years. In general, men who took PROPECIA maintained or increased the number of visible scalp hairs and noticed improvement in their hair in the first year. Improvement, compared to the start of the study, was maintained through the remaining years of treatment. Hair counts in men who did not take PROPECIA continued to decrease.

In one study, patients were questioned on the growth of body hair. PROPECIA did not appear to affect hair in places other than the scalp.


    PROPECIA is a registered trademark of Merck & Co., Inc.
20751783(2)-07/07-PRP